EMRELIS vs EXKIVITY

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 23, 2026·How we rate

Possible drug interaction. EMRELIS and EXKIVITY are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	EMRELIS	EXKIVITY
Rating	72/100	New
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	TELISOTUZUMAB VEDOTIN-TLLV	MOBOCERTINIB SUCCINATE
Manufacturer	Abbvie	Takeda Pharms USA
Dosage forms	Injectable	Capsule
Drug class	—	—
Boxed warning	None	None
Treats	Non-Small-Cell Lung Carcinoma	Non-Small-Cell Lung Carcinoma

emrelis exkivity

Rating

72/100

New

Pharmacy pays

—

Type

Active ingredient

TELISOTUZUMAB VEDOTIN-TLLV

MOBOCERTINIB SUCCINATE

Manufacturer

Abbvie

Takeda Pharms USA

Dosage forms

Injectable

Capsule

Drug class

—

Boxed warning

None

Treats

Non-Small-Cell Lung Carcinoma

Frequently asked questions

What is the difference between Emrelis and Exkivity?

Emrelis contains Telisotuzumab Vedotin-Tllv, while Exkivity contains Mobocertinib Succinate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.